BRAF Inhibition in BRAFV600-Mutant Gliomas.
BRAFV600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAFV600, in patients with gliomas that harbor this mutation. Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAFV600-mutant gliomas, […]
BRAF Inhibition in BRAFV600-Mutant Gliomas. Read More »
